Moderna says US refusing to review mRNA-based flu shotThe second Trump White House has sowed doubt over mRNA technology, which was credited with saving millions of lives during the Covid-19 pandemic. NEW YORK - Vaccine manufacturer Moderna said on Tuesday the US Food and Drug Administration (FDA) was refusing to review an application for its first mRNA-based flu shot. In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK. Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.

Source: Bangkok Post February 11, 2026 04:45 UTC